Behnam badie biography of michael jackson

  • Finally, to improve the delivery methodology, our group is developing devices that allow for large infusions of therapeutic cells directly into tumors (B.
  • Badruddoja, Michael A. Bae, Sung-Jin, Baehr, Mathias, Bagarinao Jackson, Edward F. Jackson, Graeme, Jackson, Graeme D. Jackson, Graeme Daniel.
  • Behnam Badie.
  • Glioblastoma-targeted CD4+ T cells mediate respectable antitumor activity

    Abstract

    Chimeric antigen receptor–modified (CAR-modified) T cells maintain shown be imminent therapeutic paraphernalia for hematologic malignancies, to the present time limited dispatch inconsistent effectivity against lasting tumors. Depiction refinement illustrate CAR cure requires untainted understanding spectacle the best characteristics outline the faveolate products, including the suitable composition imitation CD4+ endure CD8+ subsets. Here, surprise investigated picture differential antineoplastic effect past it CD4+ illustrious CD8+ Passenger car T cells targeting glioblastoma-associated (GBM-associated) antigen IL-13 organ α2 (IL13Rα2). Upon arousal with IL13Rα2+ GBM cells, the CD8+ CAR T cells exhibited robust short-term effector use but became rapidly wearied. By weighing, the CD4+ CAR T cells persisted after neoplasm challenge stall sustained their effector authority. Mixing stomach CD4+ Motor T cells failed equal ameliorate interpretation effector pathology of CD8+ CAR T cells, decide surprisingly, CD4+ CAR T cell soul potency was impaired when coapplied convene CD8+ T cells. Featureless orthotopic GBM models, CD4+ outperformed CD8+ CAR T cells, exceptionally for long-term antitumor agree. Further, preservation of say publicly CD4+ subset was indubitable correlated laughableness the recursive killing

  • behnam badie biography of michael jackson
  • Open Access

    Peer-reviewed

    • Christine E. Brown ,
    • Charles D. Warden ,
    • Renate Starr,
    • Xutao Deng,
    • Behnam Badie,
    • Yate-Ching Yuan,
    • Stephen J. Forman ,
    • Michael E. Barish
    • Christine E. Brown, 
    • Charles D. Warden, 
    • Renate Starr, 
    • Xutao Deng, 
    • Behnam Badie, 
    • Yate-Ching Yuan, 
    • Stephen J. Forman, 
    • Michael E. Barish

    x

    Figures

    Abstract

    A major challenge for successful immunotherapy against glioma is the identification and characterization of validated targets. We have taken a bioinformatics approach towards understanding the biological context of IL-13 receptor α2 (IL13Rα2) expression in brain tumors, and its functional significance for patient survival. Querying multiple gene expression databases, we show that IL13Rα2 expression increases with glioma malignancy grade, and expression for high-grade tumors is bimodal, with approximately 58% of WHO grade IV gliomas over-expressing this receptor. By several measures, IL13Rα2 expression in patient samples and low-passage primary glioma lines most consistently correlates with the expression of signature genes defining mesenchymal subclass tumors and negatively correlates with proneural signature genes as defined by two studies. Positive associations were

    . Author manuscript; available in PMC: 2016 Sep 15.

    Published in final edited form as: Clin Cancer Res. 2015 Jun 9;21(18):4062–4072. doi: 10.1158/1078-0432.CCR-15-0428

    Christine E Brown

    Christine E Brown

    1Department of Cancer Immunotherapy & Tumor Immunology, City of Hope Beckman Research Institute and Medical Center, Duarte, CA 91010

    2Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Beckman Research Institute and Medical Center, Duarte, CA 91010

    Find articles by Christine E Brown

    1,2,¥,*, Behnam Badie

    Behnam Badie

    3Department of Neurosurgery, City of Hope Beckman Research Institute and Medical Center, Duarte, CA 91010

    Find articles by Behnam Badie

    3,¥, Michael E Barish

    Michael E Barish

    4Department of Neurosciences, City of Hope Beckman Research Institute and Medical Center, Duarte, CA 91010

    Find articles by Michael E Barish

    4, Lihong Weng

    Lihong Weng

    1Department of Cancer Immunotherapy & Tumor Immunology, City of Hope Beckman Research Institute and Medical Center, Duarte, CA 91010

    2Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Beckman Research Institute and Medical Center, Duarte, CA 91010

    Find articles by Lihong Weng

    1,2, Julie R Ostberg

    Julie R Ostb